SCHEMBL2124645

SCHEMBL2124645

Cc1nc2c(C(F)(F)F)cccc2c(O)c1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ESR1 P03372 2/20 0.40
PARP1 P09874 1/20 0.40
PIK3CA P42336 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
TNF P01375 1/20 0.37
CXCL8 P10145 1/20 0.37
PAX8 Q06710 1/20 0.37
KLF5 Q13887 1/20 0.37
KCNH2 Q12809 6/20 0.36
ADORA2A P29274 5/20 0.36
ADORA1 P30542 5/20 0.36
CYP3A4 P08684 3/20 0.36
ADORA3 P0DMS8 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ADORA2B P29275 1/20 0.36
BACE1 P56817 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7226303 0.85 ALDH1A1 (0.43) ALDH1A1L3MBTL1ESR1PARP1KCNH2
SCHEMBL11045513 0.80 ALDH1A1 (0.45) ALDH1A1L3MBTL1ESR1PARP1MEN1
SCHEMBL2124149 0.80 ALDH1A1 (0.50) ALDH1A1L3MBTL1ESR1PARP1PIK3CA
SCHEMBL28852217 0.79 PARP1 (0.36) ALDH1A1PARP1MEN1KMT2AADORA2A
Hydrochloric Acid SCHEMBL11617104 0.79 ALDH1A1 (0.44) ALDH1A1L3MBTL1ESR1PARP1MEN1
SCHEMBL11617098 0.79 ALDH1A1 (0.44) ALDH1A1L3MBTL1ESR1PARP1MEN1
SCHEMBL2126377 0.79 KDM4E (0.49) ALDH1A1L3MBTL1PARP1MEN1KMT2A
SCHEMBL15491667 0.77 P2RX3 (0.49) ALDH1A1L3MBTL1CYP3A4
SCHEMBL15491668 0.77 ALDH1A1 (0.45) ALDH1A1L3MBTL1ESR1PARP1MEN1
SCHEMBL2123408 0.76 NR4A2 (0.47) ALDH1A1PARP1PIK3CAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
EP-2445902-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 ALDH1A1 3735/4885L3MBTL1 2670/4885ESR1 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.